Logo

Exelixis, Genomica Merger Passes End of Initial Offering Period

Jan 02, 2002

SAN FRANCISCO, Jan. 2 - The proposed Genomica-Exelixis merger reached the close of its initial offering period for the exchange of its stock on Dec. 28 at Eastern Standard Time, Exelixis said on Wednesday.

 

The companies set the ratio for converting shares of Genomica stock into shares of Exelixis stock at 0.28309 at the initial offering period's close.

 

Exelixis announced on Nov. 19 plans to acquire Genomica in a stock deal valued at $110 million, and Genomica's board of directors unanimously recommended that the firm's stockholders accept the offer, according to the company.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.